Exploring the zinc-related transcriptional landscape in Alzheimer's disease

IBRO Neurosci Rep. 2022 Jun 7:13:31-37. doi: 10.1016/j.ibneur.2022.06.002. eCollection 2022 Dec.

Abstract

Alzheimer's disease (AD) is a progressive neurological disorder, and increasing evidence suggests AD pathology is driven by metabolic dysfunction in the brain. Zinc is the second most abundant trace element found in the human body and is required by all living organisms. Zinc is used extensively in many biological processes, and alterations in zinc levels are implicated in the pathogenesis of numerous diseases, including AD. Since small fluctuations in brain zinc levels appear to effect AD progression, we investigated the zinc-related transcriptional responses in an AD versus non-AD state using microarray and RNA-sequencing (RNA-seq) datasets from cultured cells, mice, and humans. We identified 582 zinc-related differentially expressed genes (DEG) in human dorsolateral prefrontal cortex samples of late-onset AD (LOAD) versus non-AD controls, 146 zinc-related DEG in 5XFAD versus wild-type mice, and 95 zinc-related DEG in lipopolysaccharide (LPS)-stimulated N9 microglia versus unstimulated control cells, with 19 zinc-related DEG common to all three datasets. Of the 19 common DEG, functional enrichment and network analyses identified several biological processes and molecular functions, such as mRNA destabilization and nucleic acid binding, which may be important in neuroinflammation and AD development. Furthermore, therapeutic drugs targeting zinc-related DEG in the human dataset were identified. Taken together, these data provide insights into zinc utilization for gene transcription during AD progression which may further our understanding of AD pathogenesis and could identify new targets for therapeutic strategies targeted towards AD.

Keywords: AD, Alzheimer’s disease; Alzheimer’s disease; Aβ, amyloid-β; BP, biological process; CC, cellular component; CNS, central nervous system; DEG, differentially expressed genes; FC, fold change; FDR, false discovery rate; GO, gene ontology; LOAD, late-onset Alzheimer’s disease; LPS, lipopolysaccharide; MF, molecular function; Microglia; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3, nod-like receptor family pyrin domain containing 3; Neuroinflammation; RIN, RNA integrity number; RNA-seq, RNA-sequencing; Transcriptome; ZFP, zinc finger proteins; Zinc.